▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #249 by analyst upside · 2026-09-14
KYNB
Kyntra Bio, Inc.
Healthcare · Market Cap $32M · P/E 0x
ANALYST PRICE TARGET
+389.3%
implied upside to consensus target
Current Price $7.97
Consensus Target $39.0
Bull Target $43.0
Bear Target $35.0
Analysts Covering 2
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
1
Hold
1
Sell
0
52-Week Low $6.32
52-Week High $12.58
YTD Return -13.0%
FUNDAMENTALS
Market Cap $32M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-7.64
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $5M
Profit Margin 3968.6%
52-WEEK RANGE
52-Week Low $6.32
52-Week High $12.58
Current Price $7.97
Bear Target $35.0
Bull Target $43.0
● Now $7.97 ● Target $39.0
TRADING DATA
Avg Volume 15K
YTD Return -13.0%
Analyst Count 2
Consensus Buy
Upside to Target +389.3%
Last Updated 2026-09-14

ANALYST SUMMARY

Kyntra Bio, Inc. (KYNB) is currently trading at $7.97 with a Wall Street consensus price target of $39.0, implying potential upside of 389.3% over the next 12 months. 2 analysts currently cover KYNB, with a consensus rating of Buy - 50% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $43.0, while the most cautious has a target of $35.0.

KYNB operates in the Healthcare sector with a market capitalisation of $32M. The stock is down 13.0% year-to-date and is currently trading near the lower end of its 52-week range of $6.32 – $12.58.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

FBIO +336.5%
Fortress Biotech, Inc.
$84M · P/E 0.9x · Buy
AZTR +335.1%
Azitra, Inc.
$11M · P/E 8.9x · Underperform
SPRO +254.0%
Spero Therapeutics, Inc.
$66M · P/E 8.1x · Hold
PTN +353.4%
Palatin Technologies, Inc.
$21M · P/E 107.3x · Hold
CCLD +198.8%
CareCloud, Inc.
$87M · P/E 29.3x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for KYNB, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-09-01 31% win rate (48 calls)
Oppenheimer ● Initiated
Outperform 2026-07-07 14% win rate (7 calls)
Rodman & Renshaw ● Initiated
Buy 2026-06-09 29% win rate (7 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-09-24 31% win rate (48 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2025-08-07 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
25
out of 100
Coverage depth
8/30
Consensus clarity
10/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →